Companies › Clarent Biopharma
1 active drug program in 2 registered trials: 2 Phase 2; Immunology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CBP-0276 | – | Phase 2 | Hip or Knee Replacement; Psoriasis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07687966 | CBP-0276 | Phase 2 | Hip or Knee Replacement | Other | Jun 2026 |
| NCT07204639 | CBP-0276 | Phase 2 | Psoriasis | Immunology | Jul 2026 |
No annotated target.
–
Shattuck Labs Accro Bioscience (Suzhou) Mirador Therapeutics ReAlta Life Sciences Oruka Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.